Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KemPharm will initiate the development of KP511, an oral prodrug of hydromorphone, used to manage pain in patients where an opioid analgesic is appropriate.
Subscribe to our email newsletter
The drug candidate, which was identified using the Ligand Activated Therapy (LAT) approach, is the second product in the company’s pain therapy range.
KP511 demonstrated superior pharmacological characteristics reducing symptoms of constipation and limiting abuse potential.
The product candidate also has tamper resistant properties.
KemPharm CEO Travis Mickle said the discovery of KP511 would expand their opioid pain franchise and provide improved treatment outcomes for patients.